Cargando…

Drugs in secondary stroke prevention

After an ischaemic stroke or transient ischaemic attack, patients have a high risk of having another stroke. Secondary stroke prevention includes antiplatelet therapy, statins and antihypertensives Aspirin, clopidogrel, or a combination of aspirin with dipyridamole are first-line options for seconda...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremonti, Chris, Thieben, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236871/
https://www.ncbi.nlm.nih.gov/pubmed/34211246
http://dx.doi.org/10.18773/austprescr.2021.018
_version_ 1783714635064541184
author Tremonti, Chris
Thieben, Mark
author_facet Tremonti, Chris
Thieben, Mark
author_sort Tremonti, Chris
collection PubMed
description After an ischaemic stroke or transient ischaemic attack, patients have a high risk of having another stroke. Secondary stroke prevention includes antiplatelet therapy, statins and antihypertensives Aspirin, clopidogrel, or a combination of aspirin with dipyridamole are first-line options for secondary stroke prevention in the absence of atrial fibrillation Dual antiplatelet therapy has a benefit in the first three weeks after stroke, but patients should change to a single antiplatelet drug after this time Anticoagulants are indicated if the patient has atrial fibrillation. Avoid combinations of anticoagulants and antiplatelet drugs Patients should be started on statins after an ischaemic stroke. High doses are recommended even if cholesterol concentrations are normal Antihypertensive drugs are recommended for all patients with systolic blood pressures greater than 140/90 mmHg. ACE inhibitors, calcium channel blockers and diuretics are first-line options
format Online
Article
Text
id pubmed-8236871
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher NPS MedicineWise
record_format MEDLINE/PubMed
spelling pubmed-82368712021-06-30 Drugs in secondary stroke prevention Tremonti, Chris Thieben, Mark Aust Prescr Article After an ischaemic stroke or transient ischaemic attack, patients have a high risk of having another stroke. Secondary stroke prevention includes antiplatelet therapy, statins and antihypertensives Aspirin, clopidogrel, or a combination of aspirin with dipyridamole are first-line options for secondary stroke prevention in the absence of atrial fibrillation Dual antiplatelet therapy has a benefit in the first three weeks after stroke, but patients should change to a single antiplatelet drug after this time Anticoagulants are indicated if the patient has atrial fibrillation. Avoid combinations of anticoagulants and antiplatelet drugs Patients should be started on statins after an ischaemic stroke. High doses are recommended even if cholesterol concentrations are normal Antihypertensive drugs are recommended for all patients with systolic blood pressures greater than 140/90 mmHg. ACE inhibitors, calcium channel blockers and diuretics are first-line options NPS MedicineWise 2021-06-01 2021-06 /pmc/articles/PMC8236871/ /pubmed/34211246 http://dx.doi.org/10.18773/austprescr.2021.018 Text en (c) NPS MedicineWise https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Article
Tremonti, Chris
Thieben, Mark
Drugs in secondary stroke prevention
title Drugs in secondary stroke prevention
title_full Drugs in secondary stroke prevention
title_fullStr Drugs in secondary stroke prevention
title_full_unstemmed Drugs in secondary stroke prevention
title_short Drugs in secondary stroke prevention
title_sort drugs in secondary stroke prevention
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236871/
https://www.ncbi.nlm.nih.gov/pubmed/34211246
http://dx.doi.org/10.18773/austprescr.2021.018
work_keys_str_mv AT tremontichris drugsinsecondarystrokeprevention
AT thiebenmark drugsinsecondarystrokeprevention